Lubiprostone

DB01046ApprovedInvestigationalSmall moleculeChloride Channel Agonists

Lubiprostone is a prostaglandin derivative used to treat constipation caused by irritable bowel syndrome and opioid-use. Lubiprostone is a medication used in the management of idiopathic chronic constipation.

Chemical structure of Lubiprostone
Mechanism
Curator reviewed
Primary indication
Lubiprostone is indicated for the treatment of adult patients with chronic idiopathic constipation, or opioid-induced constipation in patients with chronic non-cancer pain.Curator reviewed · 3 structured indications
Formula / weight
C20H32F2O5 · 390.468 g/mol (avg)
First approval
Canada, 2015 · United States, 2006
Code names
RU-0211
Brand names
  • Amitiza

Resolves to

Structure
InChIKeyWGFOBBZOWHGYQH-MXHNKVEKSA-NSMILES[H][C@@]12CC(=O)[C@H](CCCCCCC(O)=O)[C@@]1([H])CC[C@@](O)(O2)C(F)(F)CCCC

What you can answer from here — as of October 01, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action
Listed above
1,023Drug interactionsStructured to mechanism, not free text
Sign in
39Clinical trialsPhase, status and sponsor resolved per trial
Sign in
3Structured indicationsCondition, population, route and combination as fields, not prose
Sign in
1ContraindicationEach with its own population and attribute set
Sign in
72Marketed productsAcross 7 countries and 33 labellers
Sign in
1ATC codeIncluding every combination product, plus 12 drug categories
Sign in
18+ReferencesStructured and connected to the statements they support
Sign in

Which drugs share a target with Lubiprostone, and which of those have an active Phase 3 trial?

Create a free account or log in to explore the full data card.

Create Account